{"id":701696,"date":"2022-10-27T07:59:35","date_gmt":"2022-10-27T11:59:35","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/cytosorbents-to-report-third-quarter-2022-operating-and-financial-results\/"},"modified":"2022-10-27T07:59:35","modified_gmt":"2022-10-27T11:59:35","slug":"cytosorbents-to-report-third-quarter-2022-operating-and-financial-results","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/cytosorbents-to-report-third-quarter-2022-operating-and-financial-results\/","title":{"rendered":"CytoSorbents to Report Third Quarter 2022 Operating and Financial Results"},"content":{"rendered":"
\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n
\n PRINCETON, N.J.<\/span>
\n <\/span>, Oct. 27, 2022<\/span><\/span> \/PRNewswire\/ — CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, will report third quarter 2022 operating and financial results after the market close on Thursday, November 3, 2022<\/span>. CytoSorbents’ management will host a live conference call and presentation webcast at 4:30 p.m.<\/span> Eastern the same day.<\/p>\n

\n

\n
\n \"CytoSorbents
\n <\/a>\n <\/p>\n<\/p><\/div>\n

\n Conference call details:
<\/b>
\n Date: Thursday, November 3, 2022<\/span>
<\/span>Time: 4:30 p.m.<\/span> Eastern
Toll free: 1-800-458-4121
International: 1-929-477-0402
Conference ID: 1375266<\/p>\n

The live audio webcast and presentation can be accessed via the following link: https:\/\/viavid.webcasts.com\/starthere.jsp?ei=1576192&tp_key=7e23c8c13c<\/a><\/b><\/p>\n

It is recommended that participants dial approximately 10 minutes prior to the start of the call. An archived recording of the conference call will be available under the Investor Relations portion of the company’s website at https:\/\/cytosorbents.com\/investor-relations\/financial-results\/<\/a><\/p>\n

\n About CytoSorbents Corporation (NASDAQ: <\/b>
\n
\n CTSO<\/a>
\n <\/b>
\n ) <\/b>\n <\/p>\n

\n CytoSorbents Corporation<\/a>\u00a0is a leader in the treatment of life-threatening conditions in the intensive care unit and in cardiac surgery through blood purification.\u00a0 Its lead product, CytoSorb\u00ae<\/a>, is approved in the European Union and distributed in 75 countries worldwide. It is an extracorporeal cytokine adsorber that reduces “cytokine storm” or “cytokine release syndrome” in common critical illnesses that can lead to massive inflammation, organ failure and patient death.\u00a0 In these diseases, the risk of death can be extremely high, and there are few, if any, effective treatments. CytoSorb is also used during and after cardiothoracic surgery to remove inflammatory mediators that can lead to postoperative complications, including multiple organ failure.\u00a0 As of June 30, 2022<\/span>, more than 179,000 CytoSorb devices have been used cumulatively.\u00a0 CytoSorb was originally launched in the European Union under CE mark as the first cytokine adsorber.\u00a0 Additional CE mark extensions were granted for bilirubin and myoglobin removal in clinical conditions such as liver disease and trauma, respectively, and for ticagrelor<\/a> and rivaroxaban<\/a> removal in cardiothoracic surgery procedures.\u00a0 CytoSorb has also received FDA Emergency Use Authorization<\/a> in the United States<\/span> for use in adult critically ill COVID-19 patients with impending or confirmed respiratory failure. The DrugSorb\u2122-ATR antithrombotic removal system, based on the same polymer technology as CytoSorb, also received two FDA Breakthrough Device Designations<\/a>, one for the removal of ticagrelor<\/a> and another for the removal of the direct oral anticoagulants (DOAC) apixaban and rivaroxaban<\/a> in a cardiopulmonary bypass circuit during urgent cardiothoracic procedures.\u00a0 The company has initiated two FDA-approved pivotal studies to support FDA marketing approval of DrugSorb-ATR in the United States.\u00a0 The first is the randomized, controlled STAR-T (Safe and Timely Antithrombotic Removal-Ticagrelor) study of 120 patients at 30 centers to evaluate whether intraoperative use of DrugSorb-ATR can reduce the perioperative risk of bleeding in patients receiving ticagrelor and undergoing cardiothoracic surgery.\u00a0 The second study is the STAR\u2011D\u00a0(Safe and Timely Antithrombotic Removal-Direct Oral Anticoagulants) randomized, controlled trial of 120 patients at 30 centers evaluating the intraoperative use of DrugSorb-ATR to reduce perioperative bleeding risk in patients undergoing cardiothoracic surgery and taking direct oral anticoagulants, including apixaban and rivaroxaban.<\/p>\n

CytoSorbents’ purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. \u00a0Its technologies have received non-dilutive grant, contract, and other funding of approximately $48<\/span> million\u00a0from DARPA, the U.S. Department of Health and Human Services (HHS), the National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI), the U.S. Army, the U.S. Air Force, U.S. Special Operations Command (SOCOM), Air Force Material Command (USAF\/AFMC), and others. \u00a0The Company has numerous marketed products and products under development based upon this unique blood purification technology protected by many issued U.S. and international patents and registered trademarks, and multiple patent applications pending, including ECOS-300CY\u00ae, CytoSorb-XL\u2122, HemoDefend-RBC\u2122, HemoDefend-BGA\u2122, VetResQ\u00ae, K+<\/sup>ontrol\u2122, DrugSorb\u2122, DrugSorb\u2122-ATR, ContrastSorb, and others.\u00a0\u00a0For more information, please visit the Company’s websites at\u00a0www.cytosorbents.com<\/a>\u00a0and\u00a0www.cytosorb.com<\/a>\u00a0or follow us on\u00a0Facebook<\/a>\u00a0and\u00a0Twitter<\/a>.\u00a0<\/p>\n

\n Forward-looking statements<\/b>\n <\/p>\n

This press release contains forward-looking statements that fall within the safe harbor of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements regarding our plans, objectives, future goals and prospects for our business, expectations regarding the future impact of COVID-19 or the ongoing conflict between Russia<\/span> and Ukraine<\/span>, representations and assertions, and are not historical facts and are generally identified by the use of words such as “may,” “should,” “could,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “continue” and similar terms, although some forward-looking statements are worded differently. You should be aware that the forward-looking statements in this press release reflect management’s current beliefs and expectations, but that our actual results, events and performance may differ materially from those in the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, the risks disclosed in our Annual Report on Form 10-K filed with the SEC on March 10, 2022<\/span>, our Quarterly Reports on Form 10-Q and the press releases and other communications to stockholders that we issue from time to time seeking to inform interested parties of the risks and factors that may affect our business. We caution you not to place undue reliance on such forward-looking statements. We are under no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by federal securities laws.<\/p>\n

\n
\n Please Click to Follow Us on Facebook<\/a> and Twitter<\/a><\/u>
\n <\/b>\n <\/p>\n

\n CytoSorbents Contact:<\/b>\u00a0
Kathleen Bloch<\/span>
(732) 398-5429
kbloch@cytosorbents.com<\/a><\/p>\n

\n Public Relations Contact:
<\/b>Eric Kim\u00a0
Rubenstein Public Relations
212-805-3052
ekim@rubensteinpr.com<\/a>\u00a0\u00a0<\/p>\n

<\/div>\n

\n \"Cision\" View original content to download multimedia:https:\/\/www.prnewswire.com\/news-releases\/cytosorbents-to-report-third-quarter-2022-operating-and-financial-results-301660914.html<\/a><\/p>\n

SOURCE CytoSorbents Corporation<\/p>\n<\/p><\/div>\n

\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

PR Newswire PRINCETON, N.J. , Oct. 27, 2022 \/PRNewswire\/ — CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, will report third quarter 2022 operating and financial results after the market close on Thursday, November 3, 2022. CytoSorbents’ management will host a live conference call and presentation webcast at 4:30 p.m. Eastern the same day. Conference call details: Date: Thursday, November 3, 2022Time: 4:30 p.m. EasternToll free: 1-800-458-4121International: 1-929-477-0402Conference ID: 1375266 The live audio webcast and presentation can be accessed via the following link: https:\/\/viavid.webcasts.com\/starthere.jsp?ei=1576192&tp_key=7e23c8c13c It is recommended that participants dial approximately 10 minutes prior to the start of the call. An archived recording of the … <\/p>\n

Continue reading “CytoSorbents to Report Third Quarter 2022 Operating and Financial Results”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-701696","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nCytoSorbents to Report Third Quarter 2022 Operating and Financial Results - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/cytosorbents-to-report-third-quarter-2022-operating-and-financial-results\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CytoSorbents to Report Third Quarter 2022 Operating and Financial Results - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire PRINCETON, N.J. , Oct. 27, 2022 \/PRNewswire\/ — CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, will report third quarter 2022 operating and financial results after the market close on Thursday, November 3, 2022. CytoSorbents’ management will host a live conference call and presentation webcast at 4:30 p.m. Eastern the same day. Conference call details: Date: Thursday, November 3, 2022Time: 4:30 p.m. EasternToll free: 1-800-458-4121International: 1-929-477-0402Conference ID: 1375266 The live audio webcast and presentation can be accessed via the following link: https:\/\/viavid.webcasts.com\/starthere.jsp?ei=1576192&tp_key=7e23c8c13c It is recommended that participants dial approximately 10 minutes prior to the start of the call. An archived recording of the … Continue reading "CytoSorbents to Report Third Quarter 2022 Operating and Financial Results"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/cytosorbents-to-report-third-quarter-2022-operating-and-financial-results\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2022-10-27T11:59:35+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnewswire.com\/media\/1096384\/CytoSorbents_Working_To_Save_Lives_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytosorbents-to-report-third-quarter-2022-operating-and-financial-results\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytosorbents-to-report-third-quarter-2022-operating-and-financial-results\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"CytoSorbents to Report Third Quarter 2022 Operating and Financial Results\",\"datePublished\":\"2022-10-27T11:59:35+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytosorbents-to-report-third-quarter-2022-operating-and-financial-results\\\/\"},\"wordCount\":965,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytosorbents-to-report-third-quarter-2022-operating-and-financial-results\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1096384\\\/CytoSorbents_Working_To_Save_Lives_Logo.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytosorbents-to-report-third-quarter-2022-operating-and-financial-results\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytosorbents-to-report-third-quarter-2022-operating-and-financial-results\\\/\",\"name\":\"CytoSorbents to Report Third Quarter 2022 Operating and Financial Results - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytosorbents-to-report-third-quarter-2022-operating-and-financial-results\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytosorbents-to-report-third-quarter-2022-operating-and-financial-results\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1096384\\\/CytoSorbents_Working_To_Save_Lives_Logo.jpg\",\"datePublished\":\"2022-10-27T11:59:35+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytosorbents-to-report-third-quarter-2022-operating-and-financial-results\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytosorbents-to-report-third-quarter-2022-operating-and-financial-results\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytosorbents-to-report-third-quarter-2022-operating-and-financial-results\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1096384\\\/CytoSorbents_Working_To_Save_Lives_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1096384\\\/CytoSorbents_Working_To_Save_Lives_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytosorbents-to-report-third-quarter-2022-operating-and-financial-results\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"CytoSorbents to Report Third Quarter 2022 Operating and Financial Results\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"CytoSorbents to Report Third Quarter 2022 Operating and Financial Results - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/cytosorbents-to-report-third-quarter-2022-operating-and-financial-results\/","og_locale":"en_US","og_type":"article","og_title":"CytoSorbents to Report Third Quarter 2022 Operating and Financial Results - Market Newsdesk","og_description":"PR Newswire PRINCETON, N.J. , Oct. 27, 2022 \/PRNewswire\/ — CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, will report third quarter 2022 operating and financial results after the market close on Thursday, November 3, 2022. CytoSorbents’ management will host a live conference call and presentation webcast at 4:30 p.m. Eastern the same day. Conference call details: Date: Thursday, November 3, 2022Time: 4:30 p.m. EasternToll free: 1-800-458-4121International: 1-929-477-0402Conference ID: 1375266 The live audio webcast and presentation can be accessed via the following link: https:\/\/viavid.webcasts.com\/starthere.jsp?ei=1576192&tp_key=7e23c8c13c It is recommended that participants dial approximately 10 minutes prior to the start of the call. An archived recording of the … Continue reading \"CytoSorbents to Report Third Quarter 2022 Operating and Financial Results\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/cytosorbents-to-report-third-quarter-2022-operating-and-financial-results\/","og_site_name":"Market Newsdesk","article_published_time":"2022-10-27T11:59:35+00:00","og_image":[{"url":"https:\/\/mma.prnewswire.com\/media\/1096384\/CytoSorbents_Working_To_Save_Lives_Logo.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytosorbents-to-report-third-quarter-2022-operating-and-financial-results\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytosorbents-to-report-third-quarter-2022-operating-and-financial-results\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"CytoSorbents to Report Third Quarter 2022 Operating and Financial Results","datePublished":"2022-10-27T11:59:35+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytosorbents-to-report-third-quarter-2022-operating-and-financial-results\/"},"wordCount":965,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytosorbents-to-report-third-quarter-2022-operating-and-financial-results\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/1096384\/CytoSorbents_Working_To_Save_Lives_Logo.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytosorbents-to-report-third-quarter-2022-operating-and-financial-results\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/cytosorbents-to-report-third-quarter-2022-operating-and-financial-results\/","name":"CytoSorbents to Report Third Quarter 2022 Operating and Financial Results - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytosorbents-to-report-third-quarter-2022-operating-and-financial-results\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytosorbents-to-report-third-quarter-2022-operating-and-financial-results\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/1096384\/CytoSorbents_Working_To_Save_Lives_Logo.jpg","datePublished":"2022-10-27T11:59:35+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytosorbents-to-report-third-quarter-2022-operating-and-financial-results\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/cytosorbents-to-report-third-quarter-2022-operating-and-financial-results\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytosorbents-to-report-third-quarter-2022-operating-and-financial-results\/#primaryimage","url":"https:\/\/mma.prnewswire.com\/media\/1096384\/CytoSorbents_Working_To_Save_Lives_Logo.jpg","contentUrl":"https:\/\/mma.prnewswire.com\/media\/1096384\/CytoSorbents_Working_To_Save_Lives_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytosorbents-to-report-third-quarter-2022-operating-and-financial-results\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"CytoSorbents to Report Third Quarter 2022 Operating and Financial Results"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/701696","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=701696"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/701696\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=701696"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=701696"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=701696"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}